US FDA denies Genzyme's Clolar for acute myeloid leukaemia
This article was originally published in Scrip
The US FDA has declined to approve Genzyme's oncologic agent Clolar (clofarabine) for previously untreated elderly adults with acute myeloid leukaemia (AML) absent a randomised, controlled clinical trial in this population, the company said.
You may also be interested in...
The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.
US FDA will survey health care providers’ current understanding of analgesic abuse-deterrent formulations and conduct an experimental study exploring the effectiveness of different terminology and descriptions for such products; agency has heard complaints from its own AdComms about terminology around abuse deterrence.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.